Capricor Therapeutics Announces First Subjects Dosed In Phase 1 Clinical Trial Evaluating Its StealthX Exosome-Based Vaccine

Author: Benzinga Newsdesk | August 18, 2025 08:14am

• First-in-human trial of Capricor's StealthX™ vaccine initiated under HHS's Project NextGen
• Trial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID)

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX™ exosome-based vaccine. The study, funded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) under the U.S. Department of Health and Human Services' Project NextGen, follows review and clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The trial is being conducted by an NIAID-funded network of clinical trial sites.

Posted In: CAPR